Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review

FS Zhang, QZ He, CH Qin, PJ Little, JP Weng… - Acta Pharmacologica …, 2022 - nature.com
Colchicine is an ancient herbal drug derived from Colchicum autumnale. It was first used to
treat familial Mediterranean fever and gout. Based on its unique efficacy as an anti …

Arrhythmia in COVID-19

S Babapoor-Farrokhran, RT Rasekhi, D Gill… - SN comprehensive …, 2020 - Springer
The current outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
also known as coronavirus disease 2019 (COVID-19) has quickly progressed to a global …

The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction

T Hennessy, L Soh, M Bowman, R Kurup, C Schultz… - American heart …, 2019 - Elsevier
Background Following an acute myocardial infarction (MI), patients with persistently
elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at …

Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19

AE Peter, BV Sandeep, BG Rao… - Frontiers in …, 2021 - frontiersin.org
The COVID-19 pandemic has caused a global health crisis, with no specific antiviral to treat
the infection and the absence of a suitable vaccine to prevent it. While some individuals …

A review on current repurposing drugs for the treatment of COVID-19: reality and challenges

MS Hossen, MA Barek, N Jahan… - SN comprehensive clinical …, 2020 - Springer
Abstract The coronavirus disease 2019 (COVID-19) caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic with a …

[HTML][HTML] The find of COVID-19 vaccine: Challenges and opportunities

M ElBagoury, MM Tolba, HA Nasser, A Jabbar… - Journal of infection and …, 2021 - Elsevier
Severe acute respiratory syndrome coronavirus (SARS-CoV-2), a novel corona virus,
causing COVID-19 with Flu-like symptoms is the first alarming pandemic of the third …

Gout pharmacotherapy in cardiovascular diseases: a review of utility and outcomes

S Kaul, M Gupta, D Bandyopadhyay, A Hajra… - American Journal of …, 2021 - Springer
Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV)
disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a …

The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial

H Kasiri, M Ghazaiean, N Rouhani… - Journal of …, 2023 - journals.sagepub.com
This study was designed to evaluate the effects of colchicine in the improvement of clinical
outcomes of hospitalized COVID-19 patients. This prospective, randomized, double-blind …

The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19

R Alexandrova, P Beykov, D Vassilev… - Biotechnology & …, 2021 - Taylor & Francis
SARS-CoV-2 is an emerging human beta-coronavirus that caused the COVID-19
(Coronavirus Disease− 19) pandemic, the most significant health and social crisis in the last …

Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19

M Zarei, N Sahebi Vaighan, SA Ziai - Immunopharmacology and …, 2021 - Taylor & Francis
Abstract The coronavirus disease-19 (COVID-19), at first, was reported in Wuhan, China,
and then rapidly became pandemic throughout the world. Cytokine storm syndrome (CSS) in …